IBRX - ImmunityBio, Inc. Stock Price, Fair Value and News

4.92USD-0.32 (-6.11%)Market Closed

Market Summary

USD4.92-0.32

Market Closed

-6.11%

IBRX Stock Price

View Fullscreen

IBRX RSI Chart

IBRX Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-6.05

Price/Sales (Trailing)

5.7K

EV/EBITDA

-7.48

Price/Free Cashflow

-8.89

IBRX Price/Sales (Trailing)

IBRX Profitability

EBT Margin

-93873.31%

Return on Equity

-497.03%

Return on Assets

-115.67%

Free Cashflow Yield

-11.25%

IBRX Fundamentals

IBRX Revenue

Revenue (TTM)

622.0K

Rev. Growth (Yr)

90.41%

Rev. Growth (Qtr)

69.51%

IBRX Earnings

Earnings (TTM)

-583.5M

Earnings Growth (Yr)

-115.83%

Earnings Growth (Qtr)

-143.88%

Breaking Down IBRX Revenue

Last 7 days

-15.1%

Last 30 days

2.1%

Last 90 days

39.0%

Trailing 12 Months

171.5%

How does IBRX drawdown profile look like?

IBRX Financial Health

Current Ratio

5.05

IBRX Investor Care

Shares Dilution (1Y)

54.63%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	586.0K	592.0K	556.0K	622.0K
2022	760.5K	587.0K	413.5K	240.0K
2021	687.3K	769.5K	851.8K	934.0K
2020	2.4M	2.6M	2.8M	605.0K
2019	585.8K	1.1M	1.7M	2.2M
2018	2.0M	1.4M	701.5K	47.0K
2017	3.0M	2.9M	2.8M	2.7M
2016	3.0M	3.1M	3.1M	3.1M
2015	475.0K	384.0K	364.0K	3.0M
2014	610.3K	620.5K	630.8K	641.0K
2013	0	0	0	600.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ImmunityBio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	adcock richard	sold (taxes)	-174,387	4.04	-43,165	ceo & president
Feb 05, 2024	adcock richard	acquired	-	-	83,334	ceo & president
Jan 31, 2024	sachs david c.	sold (taxes)	-90,165	3.36	-26,835	chief financial officer
Jan 31, 2024	sachs david c.	acquired	-	-	70,745	chief financial officer
Jan 31, 2024	simon barry j.	sold (taxes)	-74,235	3.36	-22,094	-
Jan 31, 2024	simon barry j.	acquired	-	-	57,200	-
Jan 31, 2024	lauer regan j	sold (taxes)	-45,259	3.36	-13,470	chief accounting officer
Jan 31, 2024	lauer regan j	acquired	-	-	32,872	chief accounting officer
Dec 31, 2023	adcock richard	acquired	-	-	34,483	ceo & president
Dec 31, 2023	adcock richard	sold (taxes)	-85,821	5.02	-17,096	ceo & president

Which funds bought or sold IBRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-25.49	-79,356	311,632	0.01%
Apr 15, 2024	Brookstone Capital Management	new	-	100,500	100,500	-%
Apr 15, 2024	WealthCare Investment Partners, LLC	unchanged	-	14,859	88,659	0.04%
Apr 12, 2024	Carlson Capital Management	added	1.14	7,234	95,586	-%
Apr 12, 2024	AdvisorNet Financial, Inc	added	285	11,770	15,535	-%
Apr 12, 2024	Traynor Capital Management, Inc.	added	31.96	35,234	120,825	0.01%
Apr 11, 2024	CENTRAL BANK & TRUST CO	unchanged	-	29.00	429	-%
Apr 09, 2024	ADIRONDACK TRUST CO	unchanged	-	288	2,416	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	628	628	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-79.66	-6,689	10,211	-%

Are Funds Buying or Selling IBRX?

Are funds buying IBRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IBRX

No. of Funds

Unveiling ImmunityBio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 04, 2024	cambridge equities, lp	39.0%	261,705,814	SC 13D/A
Sep 21, 2023	cambridge equities, lp	39.2%	261,705,814	SC 13D/A
May 23, 2023	cambridge equities, lp	60.0%	261,705,814	SC 13D/A
Dec 07, 2022	cambridge equities, lp	65.4%	261,705,814	SC 13D/A

Recent SEC filings of ImmunityBio, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	S-3	S-3
Mar 19, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 26, 2024	4	Insider Trading
Feb 06, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading

Peers (Alternatives to ImmunityBio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

ImmunityBio, Inc. News

Latest updates

ImmunityBio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	69.5%	139,000	82,000	41,000	360,000	73,000	118,000	35,000	212,500	390,000	66,000	339,000	139,000	145,000	151,000	436,000	78,000	2,168,000	1,627,750	1,087,500	547,250	7,000
Operating Expenses	6.6%	85,528,000	80,218,000	85,186,000	111,940,000	84,973,000	90,922,000	79,657,000	95,986,000	79,664,000	78,902,000	86,245,000	86,403,000	30,907,000	66,028,000	51,352,000	36,867,000	16,120,000	16,077,000	17,313,000	18,340,000	17,726,000
S&GA Expenses	4.1%	33,110,000	31,816,000	32,018,000	32,676,000	26,215,000	19,310,000	16,575,000	40,608,000	27,911,000	29,625,000	32,445,000	45,275,000	23,882,000	19,596,000	18,347,000	9,493,000	32,507,000	4,025,000	4,182,000	5,742,000	5,246,000
R&D Expenses	6.5%	51,532,000	48,402,000	53,168,000	79,264,000	58,077,000	71,612,000	63,082,000	55,378,000	51,753,000	49,277,000	53,800,000	41,128,000	43,356,000	35,772,000	33,005,000	27,374,000	74,216,000	12,052,000	13,131,000	12,598,000	12,480,000
EBITDA Margin	-24.1%	-702	-565	-588	-559	-1,399	-835	-572	-442	-343	-351	-366	-360	-	-	-	-	-	-	-	-	-
Interest Expenses	-8.3%	32,126,000	35,021,000	32,235,000	29,816,000	28,562,000	16,764,000	9,698,000	8,491,000	4,490,000	3,614,000	3,577,000	3,168,000	2,836,000	2,226,000	2,123,000	1,889,000	5,912,000	5,000	-	3,000	258,000
Income Taxes	-Infinity%	-40,000	-	-	-	34,000	-	-	-	1,000	-	2,000	6,000	-209,000	-1,700,000	45,000	18,000	-71,000	-	2,000	-36,000	-128,000
Earnings Before Taxes	-144.1%	-233,454,000	-95,642,000	-138,213,000	-116,583,000	-108,292,000	-111,161,000	-94,835,000	-102,998,000	-91,552,000	-88,429,000	-89,383,000	-80,475,000	-68,782,000	-67,870,000	-51,972,000	-37,409,000	-110,081,000	-15,581,000	-16,680,000	-17,921,000	-17,468,000
EBT Margin	-13.8%	-938	-825	-801	-735	-1,738	-968	-643	-489	-374	-384	-398	-391	-	-	-	-	-	-	-	-	-
Net Income	-143.9%	-233,105,000	-95,582,000	-138,213,000	-116,583,000	-108,005,500	-110,938,000	-94,835,000	-102,998,000	-90,277,000	-87,629,000	-89,385,000	-80,481,000	-32,132,000	-65,603,000	-51,439,000	-37,038,000	-15,641,000	-15,581,000	-16,682,000	-17,885,000	-17,340,000
Net Income Margin	-13.8%	-938	-824	-800	-734	-1,736	-965	-640	-486	-372	-340	-347	-334	-	-	-	-	-	-	-	-	-
Free Cashflow	-32.4%	-123,269,000	-93,078,000	-88,299,000	-92,738,000	-109,649,000	-96,535,000	-107,201,000	-102,277,000	-82,042,000	-80,748,000	-77,640,000	-67,552,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	16.7%	504	432	291	343	362	353	318	390	469	214	246	209	221	181	196	127	270	160	176	208	182
Current Assets	36.7%	294	215	67.00	113	141	143	115	212	334	94.00	114	100	112	98.00	115	44.00	131	72.00	87.00	113	89.00
Cash Equivalents	49.2%	265	178	44.00	88.00	105	104	62.00	36.00	181	65.00	84.00	45.00	35.00	85.00	115	59.00	76.00	18.00	17.00	22.00	17.00
Net PPE	-3.9%	146	152	151	154	144	130	119	105	83.00	70.00	89.00	81.00	73.00	56.00	59.00	59.00	83.00	62.00	65.00	68.00	77.00
Liabilities	29.3%	1,090	843	936	875	812	782	740	727	713	404	405	395	340	32.00	27.00	24.00	253	24.00	24.00	40.00	36.00
Current Liabilities	-35.5%	58.00	90.00	613	565	501	71.00	376	381	369	65.00	74.00	80.00	68.00	21.00	17.00	14.00	48.00	13.00	12.00	28.00	27.00
Shareholder's Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	117	149	14.00	103	16.00	136	151	168	82.00
Retained Earnings	-8.6%	-2,961	-2,728	-2,632	-2,500	-2,378	-2,270	-2,200	-2,064	-1,961	-1,870	-1,800	-1,700	-1,615	-722	-700	-680	-1,393	-646	-630	-613	-594
Additional Paid-In Capital	2.5%	2,375	2,316	1,991	1,966	1,931	1,844	1,740	1,729	1,720	1,682	1,625	1,509	1,495	871	870	783	1,406	783	782	782	741
Accumulated Depreciation	4.1%	84.00	81.00	78.00	73.00	69.00	65.00	61.00	57.00	53.00	50.00	48.00	45.00	42.00	25.00	23.00	21.00	28.00	16.00	14.00	12.00	12.00
Shares Outstanding	0.5%	671	668	441	422	422	400	398	398	398	392	384	383	-	-	-	-	-	-	-	-	-
Minority Interest	-2.1%	1.00	1.00	-3.07	-2.73	-2.49	-2.38	-2.16	-1.91	-1.74	-1.45	-0.65	0.00	1.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	302	-	-	-	1,051	-	-	-	415	-	-	-	29.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-31.9%	-115,314	-87,403	-79,773	-84,310	-90,727	-80,600	-91,252	-74,930	-71,639	-72,716	-69,595	-60,469	-57,604	-36,991	-46,022	-31,107	-105,632	-16,572	-16,827	-13,078	-14,033
Share Based Compensation	-11.6%	12,774	14,449	11,062	10,878	9,350	10,630	10,175	10,024	10,180	13,840	17,863	15,298	671	714	322	480	1,271	277	522	1,351	1,407
Cashflow From Investing	114.4%	2,249	-15,631	-8,604	-8,484	-18,894	-1,168	116,672	-69,313	-137,802	10,582	10,489	31,845	7,545	-56,625	15,274	13,994	9,259	17,374	11,378	-19,459	15,914
Cashflow From Financing	-15.6%	200,539	237,502	43,412	76,888	109,940	123,986	-15.00	-298	325,953	42,656	98,337	38,497	241	63,217	87,340	-123	75,625	-40.00	-501	39,195	-370
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,000	-	501	-	-

IBRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 622	$ 240	$ 934
Operating expenses:
Research and development (including amounts with related parties)	232,366	248,149	195,958
Selling, general and administrative (including amounts with related parties)	129,620	102,708	135,256
Impairment of intangible assets	886	681	0
Total operating expenses	362,872	351,538	331,214
Loss from operations	(362,250)	(351,298)	(330,280)
Other expense, net:
Interest and investment income (loss), net	1,131	(3,090)	(4,100)
Interest expense (including amounts with related parties)	(129,198)	(63,515)	(14,849)
Loss on equity method investment	(7,549)	(12,107)	(803)
Change in fair value of warrant liabilities	(47,600)	13,460	0
Change in fair value of related-party convertible note	(36,203)	0	0
Other (expense) income, net (including amounts with related parties)	(2,223)	(736)	193
Total other expense, net	(221,642)	(65,988)	(19,559)
Loss before income taxes and noncontrolling interests	(583,892)	(417,286)	(349,839)
Income tax benefit (expense)	40	(34)	(9)
Net loss	(583,852)	(417,320)	(349,848)
Net loss attributable to noncontrolling interests, net of tax	(656)	(753)	(3,058)
Net loss attributable to ImmunityBio common stockholders	$ (583,196)	$ (416,567)	$ (346,790)
Net loss per ImmunityBio common share - basic (in dollars per share)	$ (1.15)	$ (1.04)	$ (0.89)
Net loss per ImmunityBio common share - diluted (in dollars per share)	$ (1.15)	$ (1.04)	$ (0.89)
Weighted-average number of common shares used in computing net loss per share – basic (in shares)	508,635,592	399,900,374	389,234,156
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)	508,635,592	399,900,374	389,234,156

IBRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 265,453	$ 104,641
Marketable securities	1,009	2,543
Due from related parties	2,019	1,890
Prepaid expenses and other current assets (including amounts with related parties)	25,603	31,503
Total current assets	294,084	140,577
Marketable securities, noncurrent	891	840
Property, plant and equipment, net	146,082	143,659
Intangible assets, net	17,093	20,003
Convertible note receivable	6,879	6,629
Operating lease right-of-use assets, net (including amounts with related parties)	36,543	45,788
Other assets (including amounts with related parties)	2,880	4,860
Total assets	504,452	362,356
Current liabilities:
Accrued expenses and other liabilities	42,708	41,825
Related-party promissory notes, net of discounts and deferred issuance costs (Note 10)	0	431,901
Operating lease liabilities (including amounts with related parties)	5,244	2,650
Total current liabilities	58,283	500,861
Related-party nonconvertible note, net of discount (Note 10)	104,586	0
Related-party convertible notes and accrued interest, net of discount (Note 10)	576,951	241,271
Revenue interest liability (Note 9)	155,415	0
Derivative liabilities (Note 9 and Note 10)	35,333	0
Operating lease liabilities, less current portion (including amounts with related parties)	39,942	47,951
Warrant liabilities	118,770	21,636
Other liabilities	1,109	457
Total liabilities	1,090,389	812,176
Commitments and contingencies (Note 7)
Stockholders’ deficit:
Common stock, $0.0001 par value; 1,350,000,000 and 900,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 670,867,344 and 421,569,115 shares issued and outstanding as of December 31, 2023 and 2022, respectively; excluding 163,800 treasury stock shares outstanding as of December 31, 2023 and 2022	67	42
Additional paid-in capital	2,374,620	1,930,936
Accumulated deficit	(2,961,684)	(2,378,488)
Accumulated other comprehensive income	10	183
Total ImmunityBio stockholders’ deficit	(586,987)	(447,327)
Noncontrolling interests	1,050	(2,493)
Total stockholders’ deficit	(585,937)	(449,820)
Total liabilities and stockholders’ deficit	504,452	362,356
Nonrelated Party
Current liabilities:
Accounts payable	9,195	21,016
Related Party
Current assets:
Due from related parties	2,019	1,890
Current liabilities:
Accounts payable	$ 1,136	$ 3,469

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

CEO	Mr. Richard Gerald Adcock
WEBSITE	https://immunitybio.com
INDUSTRY	Biotechnology
EMPLOYEES	683

ImmunityBio, Inc. Frequently Asked Questions

What is the ticker symbol for ImmunityBio, Inc.? What does IBRX stand for in stocks?

IBRX is the stock ticker symbol of ImmunityBio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunityBio, Inc. (IBRX)?

As of Mon Apr 15 2024, market cap of ImmunityBio, Inc. is 3.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IBRX stock?

You can check IBRX's fair value in chart for subscribers.

What is the fair value of IBRX stock?

You can check IBRX's fair value in chart for subscribers. The fair value of ImmunityBio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmunityBio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IBRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmunityBio, Inc. a good stock to buy?

The fair value guage provides a quick view whether IBRX is over valued or under valued. Whether ImmunityBio, Inc. is cheap or expensive depends on the assumptions which impact ImmunityBio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBRX.

What is ImmunityBio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, IBRX's PE ratio (Price to Earnings) is -6.05 and Price to Sales (PS) ratio is 5.68 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBRX PE ratio will change depending on the future growth rate expectations of investors.